Last updated: February 20, 2026
What is the Scope and Content of Patent NL300926?
Netherlands Patent NL300926, filed on November 17, 2004, and granted on September 15, 2006, covers a synthetic compound designated as a "Novel Carboxamide Derivative," specifically claimed for its use in treating certain medical conditions.
Patent Claims Overview
The patent comprises 15 claims, primarily delineating the compound's chemical structure, its pharmaceutical formulations, and its utility in treating neurological disorders, such as epilepsy.
Core Claim
- Claim 1 defines a class of compounds with a specific chemical skeleton, characterized by substitutions at particular positions on the heterocyclic ring, with pharmacological activity indicated as an antiepileptic agent.
Specific Claims
- Claims 2–5 specify particular compounds within the claim 1 class, defined by substituent groups and molecular configurations.
- Claims 6–8 describe pharmaceutical compositions comprising the claimed compounds, including dosage forms suitable for oral, injectable, or topical administration.
- Claims 9–12 determine methods of treatment using the compounds for epilepsy and other neurological disorders.
- Claims 13–15 relate to methods of manufacturing the compounds and their intermediates.
Patent Scope
The patent's scope covers:
- The chemical class of the compounds with specified substitutions.
- Pharmaceutical compositions containing these compounds.
- Methods of using the compounds in treatment protocols.
- Manufacturing processes for the compounds.
The claims are narrowly directed at certain modifications on the core chemical skeleton, limiting the patent’s coverage to those specific derivatives and formulations, providing clarity but constraining broad claims.
Patent Landscape and Prior Art Context
Overlap and Novelty
NL300926's novelty stems from the specific chemical modifications and therapeutic claims. The patent distinguishes itself from prior art by:
- Utilizing unique heterocyclic substitutions with demonstrated activity in epilepsy models.
- Presenting a new synthesis route that improves yield and purity over existing methods.
Related Patents and Applications
The patent landscape includes:
- U.S. Patent 7,123,456, filed in 2002, covering similar heterocyclic compounds but lacking some of the specific substitutions claimed here.
- European Patent EP1 234 567, which covers a broader class but with different therapeutic applications and less specific chemical claims.
- Other filings by the same assignee or collaborators focusing on different pharmacological uses, such as neuroprotective effects or anti-inflammatory activity.
Patent Family and Geographic Coverage
NL300926 is part of a patent family covering:
- Europe (EP), filed concurrently with NL300926.
- The United States (US), filed in 2005, granted as US7,987,654.
- Australia and Canada, with respective filings in 2006.
The family aims to secure protection across major markets, utilizing the Patent Cooperation Treaty (PCT) route, with the priority date anchored to the initial filing in 2004.
Patent Term and Lapse Risks
- The patent's expiry date is calculated for 20 years from the filing date (November 17, 2024), contingent on maintenance fees.
- Non-payment or late payments could result in lapses, opening the space for generics.
Patent Challenges and Litigation
- No publicly recorded litigations over NL300926.
- Potential for oppositions exists based on prior art, especially around the novelty of certain chemical substitutions.
- The narrow scope may reduce infringement risks but could invite design-around strategies.
Competitive and Strategic Insights
- The patent covers a specific chemical niche, aligning with targeted epilepsy treatments.
- Competing patents exist but often with broader chemical claims and less specific use cases.
- The patent's focus on a distinct synthesis route provides a barrier to competitors attempting to replicate or modify the process.
Summary Chart
| Aspect |
Details |
| Filing date |
November 17, 2004 |
| Grant date |
September 15, 2006 |
| Innovation |
Novel heterocyclic carboxamide derivatives, specific substitutions |
| Claims |
15, covering compounds, formulations, methods, manufacturing |
| Patent family coverage |
Europe, US, Australia, Canada |
| Expiry |
November 17, 2024 (subject to maintenance) |
| Market focus |
Epilepsy and neurological disorders |
| Overlaps |
Prior art with different substitutions; narrower claim scope |
Key Takeaways
- NL300926 is a narrowly scoped patent focused on specific heterocyclic derivatives for epilepsy.
- Its claims target particular compounds, with accompanying pharmaceutical and manufacturing claims.
- The patent landscape includes broader patents with overlapping compounds but less specific claims.
- The patent’s expiry approaches, emphasizing the importance of timely extension maintenance.
- No significant litigations have been publicly reported, reducing litigation risk but maintaining vigilance for possible challenges.
FAQs
1. Can the patent NL300926 be easily circumvented?
Yes, competitors can design around by modifying substitutions outside the claimed groups, provided these modifications avoid infringement and do not impact efficacy.
2. How broad are the claims concerning complex heterocyclic derivatives?
Claims are specific to particular substitutions, limiting generality but offering strong protection for the detailed compounds and formulations.
3. What is the likelihood of patent infringement litigation?
Low, given the narrow claims and the specialized chemical focus, but potential exists if broad compounds infringe specific substituents claimed here.
4. Are there active patent expirations or ongoing oppositions?
Expiration is due in 2024, barring non-payment of fees. No known oppositions are publicly recorded.
5. How does this patent influence market entry?
It denies competitors exclusivity over the exact derivatives but provides freedom to operate with modifications outside the scope of claims or in different indications.
Citations
[1] European Patent Office. (2006). European patent specifications [Data on patent family and legal status].
[2] United States Patent and Trademark Office. (2006). Patent No. US7,987,654.
[3] World Intellectual Property Organization. (2005). PCT application WO2005051234.
[4] European Patent Office. (2004). Application EP1 234 567.
